EP. 4 Olaparib Combinations for Frontline Maintenance Therapy in Ovarian Cancer Treatment: The PAOLA-1 Trial
November 20th, 2026Experts Tackle Key Questions on MAPK-Directed Therapy, Frontline PARP Inhibitor Maintenance, and ADCs in Ovarian CancerGynecologic oncologists answer FAQs on LGSOC targeted therapy, PARP inhibitor maintenance, and emerging ADCs in ovarian cancer.Read more
November 15th, 2026Five Under 5: Top Oncology Videos for the Week of 11/8The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.Read more
November 11th, 2026First-Line Niraparib Maintenance Yields Longer PFS in HRD-Positive vs HRD-Negative Optimally Debulked Ovarian CancerRetrospective data tie longer survival with niraparib maintenance to homologous recombination deficiency after complete primary debulking.Read more
November 10th, 2026Mo-Rez Responses Span B7-H4 Expression Levels in Platinum-Resistant Ovarian Cancer in BEHOLD-1 Biomarker AnalysisExploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.Read more
November 10th, 2026Longer Follow-Up of BEHOLD-1 Shows Durable Responses With Mo-Rez in Platinum-Resistant Ovarian CancerUpdated BEHOLD-1 data show mocertatug rezetecan at its selected dose produced lasting responses in platinum-resistant ovarian cancer.Read more
November 9th, 2026UV1 Vaccine Data Keep hTERT in Focus as an Immunotherapy Target in Recurrent Ovarian CancerTrine Jakobi Nøttrup, MD, PhD, discusses data for the hTERT-directed vaccine UV1 in BRCA wild-type recurrent ovarian cancer.Read more